Related Experiment Video
Updated: May 16, 2026
05:19
A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance
Published on: November 7, 2025
Preoperative therapy for localized prostate cancer: a comprehensive overview
Jensen Hu1, JoAnn Hsu, Paulo G Bergerot
1Department of Medical Oncology & Experimental Therapeutics, City of Hope Comprehensive Cancer Center, Duarte, CA 91010, USA.
Maturitas
|November 20, 2012
Summary
Preoperative systemic therapy for prostate cancer, including hormonal agents and abiraterone, is under review. Its integration into clinical practice requires further evaluation of outcomes and endpoints.
Area of Science:
- Oncology
- Urology
- Pharmacology
Background:
- Localized prostate cancer treatment often involves surgery (prostatectomy).
- Preoperative systemic therapy aims to improve surgical outcomes and treat micrometastatic disease.
- Recent studies presented at the 2012 ASCO Annual Meeting highlighted hormonal therapies and abiraterone in the neoadjuvant setting.
Purpose of the Study:
- To review existing literature on preoperative systemic therapy for localized prostate cancer.
- To assess the potential incorporation of neoadjuvant treatments into clinical algorithms.
- To analyze the relevance of clinical and pathological endpoints in evaluating preoperative therapy efficacy.
Main Methods:
- MEDLINE search for prospective and retrospective clinical studies (1982-present).
- Inclusion criteria focused on studies assessing preoperative systemic therapy for prostate cancer.
- Analysis of 55 publications with more than 10 patients.
Main Results:
- Identified numerous studies on preoperative hormonal and chemotherapeutic approaches.
- Highlighted investigations into conventional hormonal therapies and novel agents like abiraterone.
- Gathered biological and clinical data from preoperative treatment studies.
Conclusions:
- Preoperative systemic therapy for prostate cancer yields significant biological insights.
- The clinical utility and integration of these neoadjuvant strategies require further investigation.
- Defining appropriate endpoints is crucial for assessing the value of preoperative prostate cancer treatments.
Related Concept Videos
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:49Cancer Therapies
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...